Abu Dhabi’s Mubadala Investment Company announced today the launch of Mubadala Bio, a life sciences company committed to strengthening the life sciences sector in the UAE and advancing better health outcomes for the UAE and the world.
The launch of this subsidiary is a strategic step that reflects Mubadala’s commitment to healthcare resilience, strengthening drug security, and expanding access to essential, high-quality therapeutics and medical devices. The company also seeks to accelerate the UAE’s economic diversification and build a knowledge-based economy.
“By launching Mubadala Bio, we are taking a transformative step towards strengthening national drug security and fostering innovation in life sciences. This positions Mubadala at the forefront of the industry, enabling us to drive long-term economic growth, build a resilient life sciences ecosystem, and elevate Abu Dhabi’s role in delivering impactful health solutions on a global scale,” stated Dr. Bakheet Al Katheeri, CEO of Mubadala’s UAE Investments Platform.
Mubadala Bio supports biopharma innovation, local manufacturing
Mubadala Bio’s integrated portfolio includes 10 facilities spanning Asia, Africa and Europe, with 6 located within the UAE, serving over 100 countries. Across these sites, the cumulative manufacturing capacity of its facilities exceeds 2.5 billion tablets and capsules, 120 million IVs and injectables annually, and spans 110,000 square meters, enabling the production and global distribution of more than 10,000 products.
Mubadala Bio’s portfolio focuses on key therapy areas that address some of the world’s most pressing health needs, supporting the full continuum of care, from prevention and diagnosis to treatment, ongoing support and complementary medicine.
By forging long-term strategic partnerships with global industry leaders and top-tier academic institutions, Mubadala Bio is accelerating biopharma innovation and local manufacturing, cultivating world-class talent and driving accelerated advancements. This holistic strategy spans the full continuum of care by providing integrated disease solutions across prevention, diagnostics, treatment, supportive treatment and complementary medicine.
Mubadala Bio to participate in Make it in the Emirates 2025
Focusing on integrated biopharma and pharma logistics, Mubadala Bio aims to support the UAE’s Centennial 2071 vision. As part of its launch, it will mark its first physical presence at Make it in the Emirates 2025, showcasing the UAE’s success in building a competitive life sciences industry and reinforcing its position as a hub for innovation and local manufacturing.
“With the launch of Mubadala Bio, we are proud to take a significant step forward in supporting the UAE’s ambition to be a global leader in the life sciences industry. By focusing on local manufacturing and enhancing our distribution and logistics capabilities, we are building a more resilient and self-sustaining life sciences sector, one that responds to today’s needs while preparing for tomorrow’s challenges,” stated Ismail Ali Abdulla, executive director of UAE Clusters at Mubadala’s UAE Investments Platform.
